# Actinium-225-Lintuzumab in Patients With Acute Myeloid Leukemia

> **NCT03705858** · PHASE1 · WITHDRAWN · sponsor: **Joseph Jurcic**

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Ac-Lintuzumab

## Key facts

- **NCT ID:** NCT03705858
- **Lead sponsor:** Joseph Jurcic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-02-28
- **Primary completion:** 2019-02-28
- **Final completion:** 2019-02-28
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Due to difficulty in finalizing the contract
- **Last updated:** 2019-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03705858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03705858, "Actinium-225-Lintuzumab in Patients With Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03705858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*